CN101175763A - 用于治疗癌症的核苷化合物的氨基磷酸酯衍生物 - Google Patents

用于治疗癌症的核苷化合物的氨基磷酸酯衍生物 Download PDF

Info

Publication number
CN101175763A
CN101175763A CNA200680016708XA CN200680016708A CN101175763A CN 101175763 A CN101175763 A CN 101175763A CN A200680016708X A CNA200680016708X A CN A200680016708XA CN 200680016708 A CN200680016708 A CN 200680016708A CN 101175763 A CN101175763 A CN 101175763A
Authority
CN
China
Prior art keywords
compound
group
alkyl
independently selected
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200680016708XA
Other languages
English (en)
Chinese (zh)
Inventor
克里斯托弗·麦圭根
肯尼思·米尔斯
克斯坦蒂诺·孔贾朱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Original Assignee
University College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd filed Critical University College Cardiff Consultants Ltd
Publication of CN101175763A publication Critical patent/CN101175763A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA200680016708XA 2005-03-21 2006-03-16 用于治疗癌症的核苷化合物的氨基磷酸酯衍生物 Pending CN101175763A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0505781.5 2005-03-21
GBGB0505781.5A GB0505781D0 (en) 2005-03-21 2005-03-21 Chemical compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410186829.5A Division CN103936807A (zh) 2005-03-21 2006-03-16 用于治疗癌症的核苷化合物的氨基磷酸酯衍生物

Publications (1)

Publication Number Publication Date
CN101175763A true CN101175763A (zh) 2008-05-07

Family

ID=34531603

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA200680016708XA Pending CN101175763A (zh) 2005-03-21 2006-03-16 用于治疗癌症的核苷化合物的氨基磷酸酯衍生物
CN201410186829.5A Pending CN103936807A (zh) 2005-03-21 2006-03-16 用于治疗癌症的核苷化合物的氨基磷酸酯衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410186829.5A Pending CN103936807A (zh) 2005-03-21 2006-03-16 用于治疗癌症的核苷化合物的氨基磷酸酯衍生物

Country Status (20)

Country Link
US (1) US8263575B2 (https=)
EP (1) EP1866324B1 (https=)
JP (2) JP5345381B2 (https=)
CN (2) CN101175763A (https=)
AT (1) ATE471334T1 (https=)
AU (1) AU2006226182C1 (https=)
BR (1) BRPI0609704B8 (https=)
CA (1) CA2602324C (https=)
CY (1) CY1111538T1 (https=)
DE (1) DE602006014949D1 (https=)
DK (1) DK1866324T3 (https=)
ES (1) ES2348741T3 (https=)
GB (1) GB0505781D0 (https=)
IL (1) IL186104A (https=)
MX (1) MX2007011666A (https=)
PL (1) PL1866324T3 (https=)
PT (1) PT1866324E (https=)
SI (1) SI1866324T1 (https=)
WO (1) WO2006100439A1 (https=)
ZA (1) ZA200709011B (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103403014A (zh) * 2011-01-03 2013-11-20 南京迈勒克生物技术研究中心 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
CN103403013A (zh) * 2011-03-01 2013-11-20 努卡那生物医药有限责任公司 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物
CN106459127A (zh) * 2014-05-28 2017-02-22 艾登尼克斯药业有限公司 用于治疗癌症的核苷衍生物
CN107207554A (zh) * 2014-11-28 2017-09-26 努卡那生物医药有限责任公司 作为抗癌化合物的新的2’和/或5’‑氨基酸酯氨基磷酸酯3’‑脱氧腺苷衍生物
CN108697636A (zh) * 2015-12-23 2018-10-23 努卡那有限公司 核苷类药物的氨基磷酸酯衍生物的制剂
CN109195981A (zh) * 2016-06-01 2019-01-11 努卡那有限公司 作为抗癌剂的氨基磷酸酯核苷衍生物
CN109563122A (zh) * 2016-06-01 2019-04-02 努卡那有限公司 用于治疗癌症的腺苷衍生物
WO2023000708A1 (zh) * 2021-07-23 2023-01-26 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
AU2012216500B2 (en) * 2006-11-24 2013-06-20 Katholieke Universiteit Leuven Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
US8759318B2 (en) 2009-01-09 2014-06-24 Inhibitex, Inc. Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
EP2658857B1 (en) * 2010-12-29 2016-11-02 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
US9085599B2 (en) 2011-03-16 2015-07-21 Enanta Pharmaceuticals, Inc. 2′allene-substituted nucleoside derivatives
SI3150616T1 (sl) 2012-11-16 2017-08-31 University College Cardiff Consultants Limited Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
CN105934438A (zh) 2013-11-27 2016-09-07 艾登尼克斯药业有限公司 用于治疗肝癌的核苷酸
KR20170005492A (ko) * 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 암의 치료를 위한 뉴클레오시드 유도체
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
CA3005444A1 (en) 2015-11-16 2017-05-26 Ichorion Therapeutics, Inc. Nucleic acid prodrugs
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US11202792B2 (en) 2016-10-12 2021-12-21 Georgetown University CD99 inhibitors and their uses
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
JP2020164521A (ja) * 2019-03-29 2020-10-08 国立大学法人 長崎大学 抗ウィルス薬
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880000094B1 (ko) * 1984-12-07 1988-02-23 보령제약 주식회사 뉴클레오시드 유도체의 제조방법
CA2004695C (en) 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
DE4418690A1 (de) 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
EP0821692B1 (en) 1995-04-21 2006-01-11 University Of South Florida Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof
JP3761958B2 (ja) * 1996-03-12 2006-03-29 彰 松田 ３′−カルバモイルアルキルヌクレオシド誘導体
IL137164A0 (en) * 1998-01-23 2001-07-24 Newbiotics Inc Enzyme catalyzed therapeutic agents
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP4768909B2 (ja) * 2000-09-29 2011-09-07 扶桑薬品工業株式会社 トポイソメラーゼ阻害剤
US20030073618A1 (en) * 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
EP1478322A4 (en) 2001-06-22 2007-08-08 Pharmasset Ltd Beta 2'-OR 3'-HALONUCLEOSIDE
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
CA2571079A1 (en) * 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2007020193A2 (en) * 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103403014B (zh) * 2011-01-03 2016-07-06 河南美泰宝生物制药有限公司 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
CN103403014A (zh) * 2011-01-03 2013-11-20 南京迈勒克生物技术研究中心 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
CN104974206B (zh) * 2011-03-01 2019-08-23 努卡那生物医药有限责任公司 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物
CN103403013A (zh) * 2011-03-01 2013-11-20 努卡那生物医药有限责任公司 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物
CN104974206A (zh) * 2011-03-01 2015-10-14 努卡那生物医药有限责任公司 用于治疗癌症的5-氟-2`-脱氧尿苷的氨基磷酸酯衍生物
CN103403013B (zh) * 2011-03-01 2016-03-16 努卡那生物医药有限责任公司 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物
CN106459127A (zh) * 2014-05-28 2017-02-22 艾登尼克斯药业有限公司 用于治疗癌症的核苷衍生物
CN107207554A (zh) * 2014-11-28 2017-09-26 努卡那生物医药有限责任公司 作为抗癌化合物的新的2’和/或5’‑氨基酸酯氨基磷酸酯3’‑脱氧腺苷衍生物
CN107207554B (zh) * 2014-11-28 2020-09-11 努卡那有限公司 作为抗癌化合物的新的2’和/或5’-氨基酸酯氨基磷酸酯3’-脱氧腺苷衍生物
CN111909231A (zh) * 2014-11-28 2020-11-10 努卡那有限公司 作为抗癌化合物的新的2’和/或5’-氨基酸酯氨基磷酸酯3’-脱氧腺苷衍生物
CN108697636A (zh) * 2015-12-23 2018-10-23 努卡那有限公司 核苷类药物的氨基磷酸酯衍生物的制剂
CN109195981A (zh) * 2016-06-01 2019-01-11 努卡那有限公司 作为抗癌剂的氨基磷酸酯核苷衍生物
CN109563122A (zh) * 2016-06-01 2019-04-02 努卡那有限公司 用于治疗癌症的腺苷衍生物
WO2023000708A1 (zh) * 2021-07-23 2023-01-26 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Also Published As

Publication number Publication date
JP2013173786A (ja) 2013-09-05
JP5863702B2 (ja) 2016-02-17
SI1866324T1 (sl) 2010-10-29
IL186104A (en) 2013-06-27
EP1866324A1 (en) 2007-12-19
CY1111538T1 (el) 2015-08-05
DE602006014949D1 (de) 2010-07-29
MX2007011666A (es) 2007-11-14
CA2602324C (en) 2015-02-24
PT1866324E (pt) 2010-09-16
US8263575B2 (en) 2012-09-11
ATE471334T1 (de) 2010-07-15
CN103936807A (zh) 2014-07-23
AU2006226182A1 (en) 2006-09-28
US20090215715A1 (en) 2009-08-27
CA2602324A1 (en) 2006-09-28
AU2006226182C1 (en) 2012-06-14
IL186104A0 (en) 2008-01-20
PL1866324T3 (pl) 2010-12-31
BRPI0609704A2 (pt) 2010-04-20
JP5345381B2 (ja) 2013-11-20
WO2006100439A1 (en) 2006-09-28
JP2008533191A (ja) 2008-08-21
ZA200709011B (en) 2009-01-28
BRPI0609704B1 (pt) 2020-12-01
DK1866324T3 (da) 2010-09-27
ES2348741T3 (es) 2010-12-13
GB0505781D0 (en) 2005-04-27
BRPI0609704B8 (pt) 2021-09-28
AU2006226182B2 (en) 2011-09-01
EP1866324B1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
CN101175763A (zh) 用于治疗癌症的核苷化合物的氨基磷酸酯衍生物
EP3235824B1 (en) Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
KR101885940B1 (ko) 암 치료에 사용하기 위한 5-플루오로-2'-데옥시우리딘의 포스포르아미데이트 유도체
EP1274713B1 (en) Anti-viral pyrimidine nucleoside analogues
CN110785175A (zh) 核苷抗代谢物的伊班膦酸盐缀合物
HK1230204B (en) Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
HK1230204A1 (en) Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
EP3810140A1 (en) Base-modified cytidine nucleotides for leukemia therapy
WO2019245444A1 (en) Base-modified cytidine nucleotides for leukemia therapy
Stec Chiral Anticancer Oxazaphosphorinanes-Stereospecific Synthesis, Configurational Assignments and Biological Evaluations
HK1210784B (en) Process for preparing nucleoside prodrugs
BR112015011155B1 (pt) Composição farmacêutica compreendendo uma mistura de rp/sp gemcitabina-[fenil- benziloxi-1- alaninil)]-fosfato

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080507